May 14, 2025
Applied Therapeutics Reports First Quarter 2025 Financial Results
– Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3…
Pharmaceuticals, Biotechnology and Life Sciences
– Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3…
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical…
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going…
– Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately…
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan…
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma…
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) — DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming…
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD)…
– Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill®…
Revenue grew 37%, driven by increased product sales and service revenueREDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Seer,…